Forty two patients with haemorrhage from peptic ulcers with visible vessels were enrolled in a randomised study comparing endoscopic haemostasis with adrenaline (1:10000) injections (adrenaline group) and adrenaline injection+neodymium yttrium-aluminium-garnet
L A Loizou, S G Bown Abstract Forty two patients with haemorrhage from peptic ulcers with visible vessels were enrolled in a randomised study comparing endoscopic haemostasis with adrenaline (1:10000) injections (adrenaline group) and adrenaline injection+neodymium yttrium-aluminium-garnet (Nd:YAG) laser photocoagulation (adrenaline +laser group). The two groups (21 patients each) were well matched for factors affecting outcome. Surgery was performed for continued haemorrhage uncontrolled by endoscopic treatment or rebleeding after two endoscopic treatments. Haemostasis after one treatment was similar in the two groups: adrenaline 16 Patients were stratified into two groups according to whether the visible vessel was actively bleeding at the time of endoscopy or not and separately randomised, by opening sealed numbered envelopes, to receive either adrenaline injection treatment or adrenaline injection+ Nd:YAG laser photocoagulation. ENDOSCOPIC 
TECHNIQUES
Endoscopic adrenaline injections were performed with a flexible injector, 0 7 mm diameter needle (Diagmed, UK), passed through the working channel of a GIF 1T20 Olympus UGI endoscope. Two ml aliquots of 1:10000 adrenaline were injected in the ulcer base in a circumferential fashion as close to the visible vessel as possible; direct injection of the vessel itself was not performed. Non-bleeding visible vessels were injected with 10-12 ml of adrenaline. When there was active bleeding larger volumes of adrenaline (up to 30 ml) were injected in an attempt to obtain haemostasis.
In patients randomised to receive combined injection and laser treatment adrenaline preinjection of the vessel was followed by photocoagulation using the Nd:YAG laser (Flexilase, Living Technology, Glasgow) which can generate a continuous wave emission of 1064 nm (near infra red) and a power output of 1-100 W. Laser light is transmitted through a 600 iim quartz fibre enclosed within a teflon catheter (2 mm diameter) which is passed down the working channel of an endoscope fitted with a safety filter in its eyepiece. A Table I . The two treatment groups were well matched for factors known to affect prognosis. Only 18% of patients in the adrenaline group and 27% in the adrenaline+Nd:YAG laser group reported dyspeptic symptoms in the two weeks preceding the index bleed. Thirty per cent of patients in the former group and 43% in the latter were taking non-steroidal antiinflammatory drugs. Nine patients (22%) were referred to this hospital for endoscopic haemostasis from outside centres as they had rebled, often repeatedly, after admission and were considered unfit for emergency surgery.
Haemostasis rates are shown in Table II Table III . The numerical difference in the emergency surgery rate for further haemorrhage between the two treatment groups was not significant (0-05<p<0 1). The implementation of a policy of endoscopic haemostasis for peptic ulcer haemorrhage using adrenaline injection or adrenaline injection+Nd:YAG laser treatment, with repeat treatment for first rebleeds, resulted in an overall emergency surgery rate of 7% and a 0% mortality. The average hospitalisation time was less than 10 days in both groups.
Active bleeding from the visible vessel was precipitated during laser treatment in two (9.5%) patients; haemorrhage was arrested by repeat adrenaline injection and further laser coagulation in both patients. In the adrenaline injection group treatment provoked spurting haemorrhage in one patient with a high posterior wall The risk of rebleeding from a visible vessel is increased further by the presence of clinical shock and a haemoglobin <80 g/l on admission'3"-"; these prognostic indicators were present in 52% and 29% of our patients respectively. Adrenaline injection treatment and combined adrenaline injection+Nd:YAG laser coagulation treatment achieved final haemostasis in 86% and 100% of these high risk patients respectively. As a result, only three patients in the adrenaline group required emergency surgery -an overall rate in the whole series of 7% -and more importantly none died as a consequence of peptic ulcer haemorrhage. The lack of deaths in this high risk subgroup assumes even greater importance if one remembers that in all patients with bleeding peptic ulcers -that is, with and without visible vessels -conservative management is associated with a mortality of around 10%.1617
The 86% final haemostasis with adrenaline 1:10000 injection in this study is similar to that reported in other series of patients with bleeding ulcers with visible vessels in which first rebleeds were also treated by repeat endoscopic treatment: Chung et al" 86%, Rutgeerts et al'2 83%. In both of these trials adrenaline injection treatment caused a pronounced reduction in rebleeding compared with conservative management. The published experience with adrenaline preinjection+Nd:YAG laser coagulation for bleeding ulcers with visible vessels is likewise limited. In two different randomised studies 
